(October 13, 2016, 5:44 PM EDT) -- WASHINGTON, D.C. — A petition by drug manufacturers asking the U.S. Supreme Court to consider “whether a reverse-payment agreement is immune from antitrust scrutiny if the consideration given by the brand-name manufacturer to the generic challenger is not a cash payment, but rather a promise to restrict its competition with the challenger after the challenger enters the market” should be denied, the U.S. solicitor general says in an Oct. 3 amicus curiae brief (SmithKline Beecham Corp., et al. v. King Drug Company of Florence Inc., No. 15-1055, U.S. Sup.)....